Subject GD-G/M-005 is an advanced PC patient with MSLN expression...Subsequently, he received intravenous infusions of the anti-MSLN-7 × 19 CAR-T cells every 1–2 months. After 5 times of the CAR-T cells infusions, CT staging revealed complete response (CR) on day 240 with the lymph node measured 8.3 × 9.6 mm and no other enlarged lymph nodes visible (Fig. 2c). He remained in normal condition. one PC patient (1/6, 16.7%) achieved CR; one HCC patient (1/6, 16.7%) achieved PR; and 2 (2/6, 33.3%) achieved steady disease (SD), demonstrating the huge therapeutic potential of 7 × 19 CAR-T cell therapy for advanced solid tumors with GPC3/MSLN expression.